Treatment-resistant PTSD is the rule among veterans, not the exception. The VA's standard of care — SSRIs, prazosin, trauma-focused therapy — works for many patients, but a substantial fraction experience inadequate response, intolerable side effects, or both. The 2019 Spravato approval for major depressive disorder with acute suicidal ideation extended ketamine-class options into VA care, but compounded racemic ketamine (the at-home form) remains outside most VA pathways.
The clinical evidence specifically for veterans is real and growing. Albott et al. (2018, Journal of Clinical Psychiatry) studied repeated IV ketamine infusions in veterans with comorbid PTSD and treatment-resistant depression and found significant, durable symptom reductions on both dimensions. Feder et al. (2014, JAMA Psychiatry) demonstrated ketamine\'s efficacy for chronic PTSD specifically. Ongoing RAND and VA cooperative studies are extending this evidence base.
The mechanism matters here. Ketamine drives glutamate-mediated neuroplasticity in the days following each session, opening a window where rigid trauma-response patterns (hypervigilance, intrusive memories, avoidance) become more malleable. For veterans engaged in concurrent trauma-focused therapy — PE, CPT, EMDR — this neuroplasticity window can substantially accelerate progress that would otherwise take years.